Stem definition | Drug id | CAS RN |
---|---|---|
4127 | 56-45-1 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
None | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal growth restriction | 92.04 | 73.26 | 15 | 93 | 7538 | 63481376 |
None
None
None
Source | Code | Description |
---|---|---|
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
CHEBI has role | CHEBI:84735 | algal metabolites |
CHEBI has role | CHEBI:78675 | fundamental metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute tuberculosis | indication | 25629007 | |
Open-angle glaucoma | indication | 84494001 | DOID:1067 |
Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
Escherichia coli urinary tract infection | indication | 301011002 | |
Bacterial urinary infection | indication | 312124009 | |
Tuberculosis of meninges | off-label use | 58437007 | |
Mycobacteriosis | off-label use | 88415009 | |
Secondary glaucoma | off-label use | 95717004 | |
Angle-closure glaucoma | off-label use | 392291006 | DOID:13550 |
Alcoholism | contraindication | 7200002 | |
Classical phenylketonuria | contraindication | 7573000 | |
Poisoning by digitalis glycoside | contraindication | 12876009 | |
Sarcoidosis | contraindication | 31541009 | DOID:11335 |
Depressive disorder | contraindication | 35489007 | |
Sideroblastic anemia | contraindication | 41841004 | DOID:8955 |
End stage renal disease | contraindication | 46177005 | DOID:784 |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Megaloblastic anemia | contraindication | 53165003 | DOID:13382 |
Heart disease | contraindication | 56265001 | DOID:114 |
Acute nephropathy | contraindication | 58574008 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Psychotic disorder | contraindication | 69322001 | |
Ventricular fibrillation | contraindication | 71908006 | |
Hypercalciuria | contraindication | 71938000 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Severe anxiety (panic) | contraindication | 80583007 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Kidney stone | contraindication | 95570007 | |
Folic acid deficiency | contraindication | 190633005 | |
Cobalamin deficiency | contraindication | 190634004 | |
CNS Toxicity | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.12 | acidic |
pKa2 | 13.26 | acidic |
pKa3 | 9.18 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Acetylcholinesterase | Enzyme | IC50 | 7.82 | CHEMBL | |||||
Cholinesterase | Enzyme | IC50 | 7.80 | CHEMBL | |||||
Gamma-glutamyltranspeptidase 1 | Enzyme | Ki | 4.30 | CHEMBL | |||||
Asc-type amino acid transporter 1 | Unclassified | IC50 | 5.02 | CHEMBL | |||||
Amino acid transporter | Transporter | IC50 | 4.24 | CHEMBL |
ID | Source |
---|---|
4018675 | VUID |
N0000146986 | NUI |
D00016 | KEGG_DRUG |
4018675 | VANDF |
C0036720 | UMLSCUI |
CHEBI:17822 | CHEBI |
SER | PDB_CHEM_ID |
CHEMBL11298 | ChEMBL_ID |
D012694 | MESH_DESCRIPTOR_UI |
DB00133 | DRUGBANK_ID |
726 | IUPHAR_LIGAND_ID |
6170 | INN_ID |
452VLY9402 | UNII |
5951 | PUBCHEM_CID |
9671 | RXNORM |
NOCODE | MMSL |
006607 | NDDF |
14125007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ProcalAmine | HUMAN PRESCRIPTION DRUG LABEL | 22 | 0264-1915 | INJECTION | 0.18 g | INTRAVENOUS | NDA | 24 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.38 g | INTRAVENOUS | NDA | 23 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.38 g | INTRAVENOUS | NDA | 23 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.38 g | INTRAVENOUS | NDA | 23 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3200 | SOLUTION | 592 mg | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-3205 | SOLUTION | 592 mg | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 592 mg | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 592 mg | INTRAVENOUS | ANDA | 20 sections |
Plenamine | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0264-4500 | SOLUTION | 592 mg | INTRAVENOUS | ANDA | 20 sections |
FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9010 | INJECTION, SOLUTION | 0.59 g | INTRAVENOUS | NDA | 24 sections |
FreAmine III | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9011 | INJECTION, SOLUTION | 0.59 g | INTRAVENOUS | NDA | 24 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9341 | SOLUTION | 0.38 g | INTRAVENOUS | NDA | 23 sections |
TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9361 | SOLUTION | 0.23 g | INTRAVENOUS | NDA | 23 sections |
HepatAmine | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0264-9371 | INJECTION, SOLUTION | 0.50 g | INTRAVENOUS | NDA | 23 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 400 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 400 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 400 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 400 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 400 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 400 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 400 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 400 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 300 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 300 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 400 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 400 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 400 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 400 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 400 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 400 mg | INTRAVENOUS | NDA | 20 sections |